Diadema Partners LP Ultragenyx Pharmaceutical Inc. Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Diadema Partners LP holds 105,500 shares of RARE stock, worth $4.69 Million. This represents 1.9% of its overall portfolio holdings.
Number of Shares
105,500Holding current value
$4.69 Million% of portfolio
1.9%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RARE
# of Institutions
344Shares Held
86.6MCall Options Held
675KPut Options Held
846K-
Vanguard Group Inc Valley Forge, PA10MShares$446 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$249 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.3MShares$191 Million0.57% of portfolio
-
State Street Corp Boston, MA2.72MShares$121 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.51MShares$112 Million0.01% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.12B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...